Related Experiment Videos
Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale
Michael A Portman1, Aaron Olson, Brian Soriano
1Seattle Children's Hospital, WA 98101, USA. michael.portman@seattlechildrens.org
Insights
Etanercept may offer a new treatment for Kawasaki disease (KD) in children unresponsive to standard care. This study investigates its effectiveness in preventing coronary artery issues in KD patients.
Area of Science:
- Pediatric Rheumatology
- Immunology
Background:
- Kawasaki disease (KD) is a critical pediatric vasculitis impacting coronary arteries.
- Standard treatments like IVIG and aspirin have limitations, particularly in refractory cases with higher coronary artery dilation rates.
Purpose of the Study:
- To evaluate the efficacy of etanercept as an adjunctive therapy for acute Kawasaki disease.
- To assess etanercept's role in reducing intravenous immunoglobulin (IVIG) resistance in KD patients.
Main Methods:
- A multicenter, double-blind, randomized, placebo-controlled trial (EATAK trial).
- 110 patients per arm receiving standard therapy plus either etanercept or placebo over two weeks.
- Coronary artery dilation parameters as secondary endpoints.
Main Results:
- This section is not available in the provided abstract.
Conclusions:
- The EATAK trial explores a novel treatment approach for acute KD.
- It investigates the potential of tumor necrosis factor-alpha (TNF-α) antagonism via etanercept in managing KD.
Background:
Kawasaki disease (KD) is a multisystem vasculitis affecting coronary arteries in children. Patients, refractory to standard treatment with intravenous immunoglobulin and aspirin, show higher rates of coronary artery dilation. Early tumor necrosis factor α receptor antagonism in KD may provide effective adjunctive therapy.
Study Design:
The EATAK trial is a multicenter, double-blind, randomized, and placebo-controlled trial intended to assess the efficacy of etanercept in reducing the intravenous immunoglobulin refractory rate during treatment of acute KD. Each arm will enroll 110 patients who will receive 3 doses of study drug over 2 weeks in conjunction with standard therapy. Coronary artery dilation parameters will serve as secondary end points.
Discussion:
The EATAK trial will test a new paradigm for treatment of acute KD involving tumor necrosis factor α antagonism by etanercept.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies
Acute Pyelonephritis II: Diagnostic Studies and Management
Rheumatic Heart Disease III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...